Brigatinib (Brigatinib) manufacturer information and latest market price

Brigatinib (Brigatinib), trade name Ambry, is an innovative treatment drug for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) developed and produced by Takeda Pharmaceuticals. With the continuous progress in the medical field and changes in market demand, the price and supply of brigatinib's original drugs and generic drugs have been updated.

1. Overview of original drug prices

The market price of brigatinib, the original drug produced by Takeda Pharmaceutical, varies depending on the specifications. Specifically, the price of 90mg 7 tablets and 4 tablets is about five to six thousand yuan; the price of 30mg 14 tablets and 2 tablets is about two to three thousand yuan; and for patients who need higher doses, the price of 180mg 7 tablets and 4 tablets is about more than 9,000 yuan. These prices reflect the investment in R&D, production and strict quality control of the original drugs.

2. Comparison of generic drug versions and prices

With the booming development of the generic drug market, multiple generic versions of brigatinib have emerged, providing patients with more economical treatment options.

1. Laos Lucius version: Trade nameLuciBriga, available in two specifications: 90mg30 tablets and 180mg30 tablets, priced at approximately more than 900 yuan and more than 1,000 yuan respectively.

2. Laos joint version: Trade nameBriganie, 90mg*30 tablets is priced at about 900 yuan, which is affordable.

3. Bangladesh international version: trade nameBiganib, available in 90mg 30 tablets and 180mg 30 tablets, priced at approximately more than 2,000 yuan and more than 3,000 yuan respectively.

4. Bangladesh Beacon version: Trade nameBriganix, although the price is relatively high, the prices of 90mg30 tablets and 180mg30 tablets are also controlled at around more than 3,000 yuan and 5,000 yuan respectively.

3. Buying Guide

Faced with many choices, patients should comprehensively consider their personal financial conditions, disease needs, and doctors’ professional advice when purchasing brigatinib. To ensure the authenticity and safety of medicines, patients are advised to purchase them through formal channels and consult professional doctors or pharmacists to obtain the most appropriate treatment plan.

In short, brigatinib is an important drug for the treatment of ALK-positive non-small cell lung cancer. The dynamic changes in price and supply of its original drugs and generic drugs provide patients with more treatment options. Patients should make wise decisions based on their actual situation and the doctor’s professional opinions in order to obtain the best treatment results.